Residual risk after SVR in advanced hepatitis C fibrosis: five-year real-world outcomes

Authors

  • Rosélia Lima Department of Internal Medicine, Gaia Espinho Local Health Unit, Portugal
  • Maria Rui Gomes Department of Internal Medicine, Gaia Espinho Local Health Unit, Portugal
  • Renata Maçano Department of Internal Medicine, Gaia Espinho Local Health Unit, Portugal
  • Carla Fagundes Department of Internal Medicine, Gaia Espinho Local Health Unit, Portugal
  • Margarida Mota Department of Internal Medicine, Gaia Espinho Local Health Unit, Portugal

DOI:

https://doi.org/10.15403/jgld-6949

Keywords:

Advanced hepatic fibrosis, Direct-acting antivirals, Hepatitis C, Sustained virological response, Hepatocellular carcinoma

Downloads

Published

2026-09-26

How to Cite

1.
Lima R, Gomes MR, Maçano R, Fagundes C, Mota M. Residual risk after SVR in advanced hepatitis C fibrosis: five-year real-world outcomes. JGLD [Internet]. 2026 Sep. 26 [cited 2026 Oct. 9];35(3):498-9. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/6949

Issue

Vol. 35 No. 3: September 2026

Section

Letters

License

Copyright (c) 2026 Journal of Gastrointestinal and Liver Diseases

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.